Intranasal Oxytocin as an Adjunct to Risperidone in Patients with Schizophrenia
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Impairment of oxytocinergic function and/or oxytocin receptor genetic abnormalities has been demonstrated in patients with schizophrenia. Oxytocin reverses emotional recognition deficit and might restore sense of trust in patients with schizophrenia. Some short-term studies have shown efficacy and tolerability of oxytocin in patients with schizophrenia. However, there is a lack of evidence on the efficacy and tolerability of oxytocin in patients with schizophrenia beyond 3 weeks.
The objective of this study was to assess the efficacy and tolerability of oxytocin intranasal spray (given as an adjuvant to risperidone) in patients with schizophrenia.
This was an 8-week, randomized, double-blind, placebo-controlled study.
Inpatients of two large referral psychiatric hospitals in Iran were recruited for the study.
Forty patients (male and female gender) aged 18–50 years with a diagnosis of schizophrenia (DSM-IV-TR) who were on a stable dose of risperidone for a minimum of 1 month and who were chronically partially responsive to antipsychotic monotherapy were included in the study.
The patients were randomly assigned to oxytocin intranasal spray (Syntocinon®; Novartis, Basel, Switzerland) or placebo intranasal spray containing normal saline (ACER, Tehran, Iran) for 8 weeks. Oxytocin spray was administered as 20 IU (five sprays) twice a day for the first week followed by 40 IU (ten sprays) twice a day for the following 7 weeks. Placebo spray was administered at the same dose as the oxytocin spray. In addition, participants were on a stable dose of risperidone (5 or 6 mg/day).
The patients were assessed using Positive and Negative Syndrome Scale (PANSS) at baseline and at weeks 0, 2, 4, 6 and 8. Primary outcomes were the differences in the PANSS scores between the two groups at the end of the trial. Adverse effects were recorded using a checklist and the Extrapyramidal Symptom Rating Scale (ESRS) at baseline and at weeks 1, 2, 4, 6 and 8.
All patients had at least one post-baseline measurement and 37 patients (19 in the oxytocin and 18 in the placebo group) completed the study. Repeated measure analysis of variance showed significant effect for time X treatment interaction on the PANSS total [F(2.291,87.065) = 22.124, p < 0.001], positive [F(1.285,48.825) = 11.655, p = 0.001], negative [F(2.754,104.649) = 11.818, p < 0.001] and general psychopathology [F(1.627,61.839) = 4.022, p = 0.03] subscale scores. By week 8, patients in the oxytocin group showed significantly greater improvement on the positive (Cohen’s d = 1.2, 20 % vs. 4 % reduction in score, p < 0.001), negative (Cohen’s d = 1.4, 7 % vs. 2 % reduction in score, p < 0.001) and general psychopathology (Cohen’s d = 0.8, 8 % vs. 2 % reduction in score, p = 0.021) subscales and total (Cohen’s d = 1.9, 11 % vs. 2 % reduction in score, p < 0.001) PANSS scores than the placebo group. Adverse effects including the sodium concentration change were similar between the two groups.
Oxytocin as an adjunct to risperidone tolerably and efficaciously improves positive symptoms of schizophrenia. In addition, effects on negative and total psychopathology scores were statistically significant, but likely to be clinically insignificant. The interesting findings from the present pilot study need further replication in a larger population of patients.
- Lee HJ, Macbeth AH, Pagani JH, et al. Oxytocin: the great facilitator of life. Prog Neurobiol. 2009;88(2):127–51.
- Ditzen B, Schaer M, Gabriel B, et al. Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol Psychiatry. 2009;65(9):728–31. CrossRef
- Heinrichs M, Baumgartner T, Kirschbaum C, et al. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry. 2003;54(12):1389–98. CrossRef
- Zak PJ. The neurobiology of trust. Sci Am. 2008 Jun;298(6):88–92, 95.
- Baumgartner T, Heinrichs M, Vonlanthen A, et al. Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron. 2008;58(4):639–50. CrossRef
- Guastella AJ, Mitchell PB, Dadds MR. Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry. 2008;63(1):3–5. CrossRef
- Petrovic P, Kalisch R, Singer T, et al. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. J Neurosci. 2008;28(26):6607–15. CrossRef
- Teltsh O, Kanyas-Sarner K, Rigbi A, et al. Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree. Int J Neuropsychopharmacol. Epub 2011 Sep 7.
- Souza RP, Ismail P, Meltzer HY, et al. Variants in the oxytocin gene and risk for schizophrenia. Schizophr Res. 2010;121(1–3):279–80. CrossRef
- Averbeck BB, Bobin T, Evans S, et al. Emotion recognition and oxytocin in patients with schizophrenia. Psychol Med. Epub 2011 Aug 11.
- Goldman MB, Gomes AM, Carter CS, et al. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology (Berl). 2011;216(1):101–10. CrossRef
- Rosenfeld AJ, Lieberman JA, Jarskog LF. Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. Schizophr Bull. 2011;37(5):1077–87. CrossRef
- Braff DL, Geyer MA, Light GA, et al. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res. 2001;49(1–2):171–8. CrossRef
- Martinez ZA, Halim ND, Oostwegel JL, et al. Ontogeny of phencyclidine and apomorphine-induced startle gating deficits in rats. Pharmacol Biochem Behav. 2000;65(3):449–57. CrossRef
- Caldwell HK, Stephens SL, Young WS 3rd. Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol Psychiatry. 2009;14(2):190–6. CrossRef
- Lee PR, Brady DL, Shapiro RA, et al. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology. 2005;30(10):1883–94. CrossRef
- Feifel D, Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology (Berl). 1999;141(1):93–8. CrossRef
- Feifel D, Shilling PD, Belcher AM. The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. Eur Neuropsychopharmacol. 2012;22(5):374–8. CrossRef
- Uvnas-Moberg K, Alster P, Svensson TH. Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in rats. Psychopharmacology (Berl). 1992;109(4):473–6. CrossRef
- Pedersen CA, Gibson CM, Rau SW, et al. Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophr Res. 2011;132(1):50–3. CrossRef
- Feifel D, Macdonald K, Nguyen A, et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry. 2010;68(7):678–80. CrossRef
- First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition. New York: Biometrics Research, New York State Psychiatric Institute; 2002.
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76. CrossRef
- Akhondzadeh S, Mohammadi N, Noroozian M, et al. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res. 2009;107(2–3):206–12. CrossRef
- Akhondzadeh S, Ghayyoumi R, Rezaei F, et al. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology (Berl). 2011;213(4):809–15. CrossRef
- Ghaleiha A, Noorbala AA, Farnaghi F, et al. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. J Clin Psychopharmacol. 2010;30(6):678–82. CrossRef
- Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76(2–3):247–65. CrossRef
- Ishak WW, Kahloon M, Fakhry H. Oxytocin role in enhancing well-being: a literature review. J Affect Disord. 2011;130(1–2):1–9. CrossRef
- Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull. 2006;32(Suppl. 1):S44–63. CrossRef
- Ross HE, Young LJ. Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior. Front Neuroendocrinol. 2009;30(4):534–47. CrossRef
- Bartz JA, Hollander E. The neuroscience of affiliation: forging links between basic and clinical research on neuropeptides and social behavior. Horm Behav. 2006;50(4):518–28. CrossRef
- Feldman R. Oxytocin and social affiliation in humans. Horm Behav. 2012;61(3):380–91. CrossRef
- Neumann ID. Brain oxytocin: a key regulator of emotional and social behaviours in both females and males. J Neuroendocrinol. 2008;20(6):858–65. CrossRef
- Rubin LH, Carter CS, Drogos L, et al. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res. 2010;124(1–3):13–21. CrossRef
- Rubin LH, Carter CS, Drogos L, et al. Sex-specific associations between peripheral oxytocin and emotion perception in schizophrenia. Schizophr Res. 2011;130(1–3):266–70. CrossRef
- Murakami G, Hunter RG, Fontaine C, et al. Relationships among estrogen receptor, oxytocin and vasopressin gene expression and social interaction in male mice. Eur J Neurosci. 2011;34(3):469–77. CrossRef
- Leon AC. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments. J Clin Psychiatry. 2004;65(11):1511–4. CrossRef
- Intranasal Oxytocin as an Adjunct to Risperidone in Patients with Schizophrenia
Volume 27, Issue 1 , pp 57-65
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing AG
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, 13337, Iran
- 2. Department of Psychiatry, Kurdistan University of Medical Sciences, Sanandaj, Iran
- 3. Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran
- 4. Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
- 5. Research Center for Behavioral Disorders and Substance Abuse, Hamadan University of Medical Sciences, Hamadan, Iran